In User Fee Talks, FDA Investigates Pre-market Review Delays
This article was originally published in The Gray Sheet
Executive Summary
As FDA user fee negotiations move ahead, the agency is conducting a root cause analysis to determine why the time it takes to complete pre-market device reviews is increasing.
You may also be interested in...
Journal Editors Slam Industry-Funded Device Approval Studies
The editors of three premier peer-reviewed medical journals say two widely circulated reports criticizing FDA's medical device review process are deeply flawed, biased and should play no part in discussions over FDA regulatory reforms.
Journal Editors Slam Industry-Funded Device Approval Studies
The editors of three premier peer-reviewed medical journals say two widely circulated reports criticizing FDA's medical device review process are deeply flawed, biased and should play no part in discussions over FDA regulatory reforms.
FDA Device Center Analyzes Why It Missed PMA Review Goals
FDA pre-market approval reviews tend to take longer when the medical officer leaves the review team, when clinical trial data issues arise and when companies engage in "excessive" back and forth with FDA during the review process, according to a recent FDA analysis.